Journal List > Infect Chemother > v.47(3) > 1035355

TOOLS
Bae, Kang, Jang, Lee, Kim, Kim, Jeong, and Lee: Detection of Carbapenemases in Clinical Enterobacteriaceae Isolates Using the VITEK AST-N202 Card
Original Article

Infection & Chemotherapy 2015; 47(3): 167-174.

Published online: 30 September 2015

DOI: https://doi.org/10.3947/ic.2015.47.3.167

Detection of Carbapenemases in Clinical Enterobacteriaceae Isolates Using the VITEK AST-N202 Card

Il Kwon Bae1, Hyun-Kyung Kang1, In-Ho Jang2, Woonhyoung Lee3, Keonhan Kim4, Jung Ok Kim4, Seok Hoon Jeong4, Kyungwon Lee4

1Department of Dental Hygiene, Silla University, Busan, Korea.

2Department of Biomedical Laboratory Science, College of Health Sciences, Sangji University, Wonju, Gangwon, Korea.

3Department of Laboratory Medicine, Kosin University College of Medicine, Busan, Korea.

4Department of Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei University College of Medicine, Seoul, Korea.

Corresponding Author: Seok Hoon Jeong, MD, PhD. Department of Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei University College of Medicine, 211 Eonjuro, Gangnam-gu, Seoul 06273, Korea. Tel: +82-2-2228-2448, Fax: +82-2-313-0956, kscpjsh@yuhs.ac

Received 12 May 2015       Revised 2 June 2015       Accepted 3 June 2015

Copyright © 2015 by The Korean Society of Infectious Diseases and Korean Society for Chemotherapy

(open-access):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

The rapid and accurate detection of carbapenemase-producing Enterobacteriaceae (CPE) in clinical microbiology laboratories is essential for the treatment and control of infections caused by these microorganisms. This study was performed to evaluate the ability of the VITEK AST-N202 card to detect CPE isolates.

Materials and Methods

A total of 43 (Klebsiella pneumoniae, n = 37; Escherichia coli, n = 3; and Enterobacter cloacae, n = 3) CPE isolates and 79 carbapenemase-non-producing Enterobacteriaceae (CNE) isolates were included in this study. The CPE isolates harbored KPC-2 (n = 11), KPC-3 (n = 20), GES-5 (n = 5), VIM-2 (n = 2), IMP-1 (n = 1), NDM-1 (n = 2), or OXA-232 (n = 2). Of the 79 CNE isolates, eight K. pneumoniae isolates were resistant to ertapenem, imipenem, and meropenem, while the remaining 71 isolates were susceptible to the carbapenems. Antimicrobial susceptibilities were tested using the VITEK AST-N202 card, and the results were interpreted as positive when the isolates showed resistant or intermediate results. Modified-Hodge tests (MHTs) were performed using ertapenem or meropenem disks for the screening of carbapenemase production. Polymerase chain reaction (PCR) and direct sequencing were used to identify β-lactamase genes.

Results

Sensitivity of MHT with ertapenem and meropenem disks for the detection of carbapenemase was 81.4% (35/43) and 81.4% (35/43), respectively, and a combination with both antibiotic disks increased the sensitivity to 88.4% (38/43). Specificity of the MHT was 100% (79/79) for the CNE isolates. Sensitivity of ertapenem, imipenem, and meropenem as assessed by the VITEK AST-N202 card was 100% (43/43), 93% (40/43), and 95.3% (41/43), respectively. Specificity (89.8%, 71/79) of the test with each carbapenem was improved to 100% (71/71) when eight carbapenem-resistant CNE isolates were excluded from the testing.

Conclusion

The VITEK AST-N202 card showed high sensitivity for the detection of carbapenemases in Enterobacteriaceae strains. PCR and sequencing experiments for the detection of carbapenemases are recommended when clinical Enterobacteriaceae isolates show non-susceptibility to carbapenems.

Keywords: Carbapenemase-producing Enterobacteriaceae, VITEK AST-N202 card, KPC, GES, NDM

Introduction

Carbapenems have been used as the drug of choice for the treatment of infections caused by multi-drug resistant Gram-negative rods because these drugs easily permeate the porins of outer cellular membranes, exhibit high affinity with penicillin-binding proteins, and are stable against various β-lactamases produced by Gram-negative rods [1234]. However, carbapenem-resistant Enterobacteriaceae (CRE) has appeared as a consequence of the frequent use of these drugs for the treatment of widespread extended-spectrum β-lactamase- and/or AmpC β-lactamase-producing Enterobacteriaceae [5]. Dissemination of CRE is considered a serious clinical threat because available antimicrobials for the treatment of infections caused by CRE are very limited.
Although Enterobacteriaceae can acquire carbapenem resistance via various mechanisms, the most important one is the production of plasmid-mediated carbapenemases [5]. Diverse types of carbapenemases have appeared in Enterobacteriaceae, including 1) KPC- and GES-type enzymes belonging to class A, 2) IMP-, VIM-, and NDM-type metallo-β-lactamases (MBLs) belonging to class B, and 3) OXA-48 and its variants belonging to class D. Enterobacteriaceae strains producing these various carbapenemases have already appeared in Korea [6].
The rapid and accurate detection of carbapenemase-producing Enterobacteriaceae (CPE) in clinical laboratories is essential for the treatment of infections and infection control. However, the identification of CPE strains can be difficult because some CPE clinical isolates exhibit low-level resistance or susceptibility to carbapenems [7]. This study was performed to evaluate the ability of VITEK AST-N202 cards (bioMérieux, Marcy l'Etoile, France) to reliably detect CPE strains isolated from a clinical setting.

Materials and Methods

1. Bacterial strains and susceptibility testing

A total of 122 Enterobacteriaceae clinical isolates, 43 CPE and 79 carbapenemase-non-producing Enterobacteriaceae (CNE), were included in this study (Table 1). The CPE clinical isolates were identified as follows: 37 Klebsiella pneumoniae, three Escherichia coli, and three Enterobacter cloacae. The CPE clinical isolates produced KPC-2 (n = 11), KPC-3 (n = 20), GES-5 (n = 5), VIM-2 (n = 2), IMP-1 (n = 1), NDM-1 (n = 2), and OXA-232 (n = 2) carbapenemases. Of the 79 CNE clinical isolates, eight K. pneumoniae isolates were resistant to ertapenem, imipenem, and meropenem, while the remaining 71 isolates were susceptible to these carbapenems; E. coli (n = 35), K. pneumoniae (n = 17), Klebsiella oxytoca (n = 1), E. cloacae (n = 1), Enterobacter aerogenes (n = 6), Enterobacter asburiae (n = 2), Serratia marcescens (n = 4), Citrobacter freundii (n = 1), Citrobacter koseri (n = 1), Morganella morganii (n = 2), and Proteus mirabilis (n = 1). Bacterial species were identified using matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS) (Bruker Daltonics, Bremen, Germany) and by analysis of partial 16S rDNA sequences. Antimicrobial susceptibilities of the clinical isolates were determined using VITEK AST-N202 cards (bioMérieux, Table 2). Genes encoding β-lactamases, including TEM-, SHV-, CTX-M-, GES-, and KPC-types of class A; IMP-, VIM-, and NDM-types of class B; CMY-1-, CMY-2-, and DHA-types of class C; and OXA-48-types of class D, were identified by PCR and sequencing (Table 3) [891011].

2. Detection of carbapenemases

Carbapenemases were screened using VITEK AST-N202 cards and modified Hodge tests (MHTs). If an isolate exhibited intermediate or resistance designations to more than one of the carbapenems, ertapenem, imipenem, or meropenem, based on the VITEK AST-N202 card, then the isolate was considered CPE. MHTs were performed with ertapenem and meropenem disks, separately, as described previously [12]. Briefly, a suspension of E. coli ATCC 25922 at a 0.5 McFarland turbidity unit concentration was spread on the entire surface of a MacConkey agar (Becton and Dickinson Company, Sparks, MD, USA) plate. Disks containing ertapenem or meropenem (10 µL, Becton and Dickinson Company) were placed on the center of the agar using a cotton swab, and then the clinical isolates were thickly inoculated from the edge of the disk to the periphery of the agar using a platinum loop. After overnight incubation, if a thickening of the inoculation line of a clinical isolate was observed on the edge of an inhibition zone, then the isolate was considered a CPE strain.

Results

1. Ability of MHTs to identify CPE strains

Of the 43 CPE isolates, 35 (81.4%) exhibited positive results in the MHTs with ertapenem or meropenem disks. In the ertapenem MHTs, eight CPE isolates showed false-negative results, including KPC-2-producing K. pneumoniae (n = 1), GES-5-producing K. pneumoniae (n = 2), NDM-1-producing K. pneumoniae (n = 1), GES-5-producing E. coli (n = 1), OXA-232-producing E. coli (n = 1), and VIM-2-producing E. cloacae (n = 2). In the meropenem MHTs, eight CPE isolates showed false-negative results, including KPC-2-producing K. pneumoniae (n = 2), KPC-3-producing K. pneumoniae (n = 1), GES-5-producing K. pneumoniae (n = 1), GES-5-producing E. coli (n = 1), OXA-232-producing E. coli (n = 1), and VIM-2-producing E. cloacae (n = 2). Five CPE isolates showed false-negative results in both ertapenem and meropenem MHTs, including GES-5-producing K. pneumoniae (n = 1), GES-5-producing E. coli (n = 1), OXA-232-producing E. coli (n = 1), and VIM-2-producing E. cloacae (n = 2). All 79 CNE isolates showed negative results regardless of carbapenem susceptibility. Sensitivities of the ertapenem and meropenem MHTs for CPE were both 81.4% (35/43), and that was increased to 88.4% (38/43) when the MHTs were performed with both antibiotics. Specificity of the MHTs was 100% (79/79) (Table 4).

2. Ability of the VITEK AST-N202 card to identify CPE strains

In antimicrobial susceptibility testing using VITEK AST-N202 cards, all 43 CPE isolates exhibited resistance to ertapenem, while only 38 and 41 of the CPE isolates showed resistance to imipenem and meropenem, respectively. Two and three CPE isolates exhibited intermediate and susceptibility patterns to imipenem, respectively, and two isolates were susceptible to meropenem. Three isolates exhibiting susceptibility patterns to imipenem included one GES-5-producing E. coli isolate and two OXA-232-producing E. coli isolates. Two isolates exhibited susceptibility to meropenem, including one GES-5-producing E. coli isolate and one OXA-232-producing E. coli isolate. Of the 79 CNE isolates, eight exhibited resistance to ertapenem, imipenem, and meropenem, while the remaining 71 isolates were susceptible to these carbapenems. Sensitivities to ertapenem, imipenem, and meropenem of the CPE strains when assessed using the VITEK AST-N202 cards were 100% (43/43), 88.4% (38/43), and 95.3% (41/43), respectively. Sensitivity of the VITEK 2 AST-N202 cards for the CPE strains when using all three carbapenems was 100%. Specificities of the three carbapenems for CPE strains using the VITEK AST-N202 cards were all 89.8% (71/79); however, that reached 100% (71/71) when the eight carbapenem-resistant clinical CNE isolates were excluded (Table 4).

Discussion

Although the prevalence of CPE strains is still low (<1%) in Korea, various types of carbapenemases have been identified (Table 4). Since the first isolation of S. marcescens-producing class B VIM-2 MBL in Korea in 2002, VIM-2-producing E. cloacae have repeatedly been reported (Table 5) [13141516171819202122232425]. An outbreak of NDM-1-producing K. pneumoniae sequence type 340 (ST340) was reported in 2012, and the NDM-1-producing E. coli ST101 strain appeared in Korea in 2013 [26]. In a nationwide survey of antimicrobial resistance performed in 2003, a class A GES-5 carbapenemase was first identified in two clinical K. pneumoniae isolates from a hospital in Gyeonggi province, and an outbreak caused by the strain occurred in that same hospital in the next year [19]. Furthermore, a GES-5-producing E. coli ST131 was detected in 2011 [18]. An infection caused by the KPC-2-producing K. pneumoniae ST11 strain was first reported in 2010; thereafter, outbreaks caused by the KPC-2-producing K. pneumonia ST258 strain have been repeatedly reported in several hospitals in Korea [1314]. In 2014, an outbreak caused by K. pneumoniae ST14-producing OXA-232, a variant of class D OXA-48, occurred in a hospital in Seoul, Korea, and E. coli isolates producing this carbapenemase were also detected from rectal swab specimens [25]. Therefore, the development of rapid and accurate methods for the detection of CPE is needed for adequate treatment of infections caused by these microorganisms and for prevention of further dissemination.
Recently, the Clinical and Laboratory Standard Institute (CLSI) recommended MHTs with ertapenem disks as the standard detection method for CPE strains [12]. This study was performed to compare the ability of ertapenem and meropenem MHTs with VITEK AST-N202 cards. Both ertapenem and meropenem MHTs detected 35/43 (81.4%) CPE isolates, and sensitivity was increased to 88.4% (38/43) when the MHTs were performed with both carbapenem disks. The results indicate that the detection of CPE strains is dependent on whether MHTs fail in some cases, especially in cases of CPE strains harboring carbapenemases (GES-5, OXA-232, and MBLs) other than KPC. Ertapenem susceptibility testing using the VITEK AST-N202 card detected all 43 CPE isolates as resistant, while three and two CPE isolates respectively exhibited susceptibility patterns to imipenem and meropenem using this commercial card. CPE isolates harboring GES-5 or OXA-232 exhibited susceptibility to these carbapenems. The results suggest that CPE detection must be conducted based on ertapenem susceptibility when using VITEK AST-N202 cards.
In conclusion, the VITEK AST-N202 card showed excellent performance for the detection of CPE strains. It is recommended that ertapenem-resistant Enterobacteriaceae clinical isolates should be directly subjected to molecular diagnostic methods for the identification of carbapenemase genes, because MHTs did now show sufficient sensitivity for the detection of CPEs.

Figures and Tables

Table 1

Characteristics of carbapenem-resistant Enterobacteriaceae

ic-47-167-i001
Strain β-Lactamase Modified-Hodge test Antimicrobial susceptibilitya
Carbapenemase Others Ertapenem Meropenem Ertapenem Imipenem Meropenem
Klebsiella pneumoniae KPC-2 SHV-12, SHV-1, TEM-1 + + R R R
KPC-2 SHV-12, SHV-1, TEM-1 + + R R R
KPC-2 SHV-12, SHV-1, TEM-1 + + R R R
KPC-2 SHV-12, SHV-1, TEM-1 + + R R R
KPC-2 SHV-12, SHV-1, TEM-1 + + R R R
KPC-2 SHV-12, SHV-11 + - R R R
KPC-2 SHV-11, TEM-1 + + R R R
KPC-2 TEM-1 + + R R R
KPC-2 - + R R R
KPC-2 + + R R R
KPC-2 + - R R R
KPC-3 SHV-12, TEM-1, CMY-2 + + R R R
KPC-3 SHV-12, SHV-1, TEM-1 + + R R R
KPC-3 SHV-12, SHV-1, TEM-1 + + R R R
KPC-3 SHV-12, SHV-1, TEM-1 + + R R R
KPC-3 SHV-12, SHV-1, TEM-1 + - R R R
KPC-3 SHV-12, SHV-1, TEM-1 + + R R R
KPC-3 SHV-12, SHV-1, TEM-1 + + R R R
KPC-3 SHV-12, SHV-1, TEM-1 + + R R R
KPC-3 SHV-12, SHV-1, TEM-1 + + R R R
KPC-3 SHV-12, SHV-1, TEM-1 + + R R R
KPC-3 SHV-12, SHV-1, TEM-1 + + R R R
KPC-3 SHV-12, SHV-1, TEM-1 + + R R R
KPC-3 SHV-12, SHV-1, TEM-1 + + R R R
KPC-3 SHV-12, SHV-1, TEM-1 + + R R R
KPC-3 SHV-12, SHV-1, TEM-1 + + R R R
KPC-3 TEM-1 + + R R R
KPC-3 + + R R R
KPC-3 + + R R R
KPC-3 + + R R R
KPC-3 + + R R R
GES-5 SHV-12 + + R R R
GES-5 SHV-12 + + R R R
GES-5 SHV-12 - + R I R
GES-5 SHV-12, CMY-2 - - R I R
NDM-1 - + R R R
NDM-1 + + R R R
Escherichia coli GES-5 - - R S S
OXA-232 + + R S R
OXA-232 - - R S S
Enterobacter cloacae VIM-2 - - R R R
VIM-2 - - R R R
IMP-1 + + R R R
Klebsiella pneumoniae CTX-M-3, SHV-12, DHA-1, TEM-1 - - R R R
CTX-M-14, SHV-2a, DHA-1 - - R R R
CTX-M-14, SHV-12, DHA-1 - - R R R
CTX-M-15, DHA-1 - - R R R
SHV-12, DHA-1 - - R R R
DHA-1 - - R R R
DHA-1 - - R R R
SHV-1, CMY-1 - - R R R

aAntimicrobial susceptibility was tested using the VITEK AST-N202 card.

Table 2

Carbapenem disk contents of the VITEK AST-N202 card

ic-47-167-i002
Carbapenem disk Indication MIC (µg/mL) MIC interpretive criteria (µg/mL) FDA indication for use
Susceptible Resistance
Ertapenem 0.5, 1, 6 0.5 8 E. coli, K. pneumonia, Citrobacter freundii, Citrobacter koseri, Enterobacter aerogenes, E. cloacae, Koxa (-ESBL), Morganella morganii, Proteus mirabilis, Proteus vulgaris, S. marcescens
Imipenem 1, 2, 6, 12 0.25 16 Acinetobacter spp., Citrobacter spp., Enterobacter spp., E. coli, Klebsiella spp., M. morganii, P. vulgaris, Providencia rettgeri, P. aeruginosa, S. marcescens, Providencia stuartii
Meropenem 0.5, 2, 6, 12 0.25 16 E. coli, K. pneumoniae, P. aeruginosa, P. mirabilis, Acinetobacter spp., C. freundii, E. cloacae, K. oxytoca, M. morganii, P. vulgaris, S. marcescens, Aeromonas hydrophila, Citrobacter diversus, Hafnia alvei, Pasteurella multocida, Salmonella spp., Shigella spp.

aKlebsiella oxytoca (excluding ESBL-producing strains)

MIC, minimal inhibitory concentration; FDA, Food and Drug Administration; ESBL, extended-spectrum β-lactamase.

Table 3

Nucleotide sequences of primers used in this study

ic-47-167-i003
Primer name Target gene Nucleotide sequence (5' to 3') Product size (bp) Reference
KPC-F KPC-type GTCACTGTATCGCCGTCTAGTTC 909 This study
KPC-R TGGTGGGCCAATAGATGATT
GES-F GES-type CGCTTCATTCACGCACTATT 855 [8]
GES-R GTCCGTGCTCAGGATGAGTT
IMP-1F IMP-1 variants AAGGCGTTTATGTTCATACTTCG 605 This study
IMP-1R TTTAACCGCCTGCTCTAATGTAA
VIM-2F VIM-2 variants ATCATGGCTATTGCGAGTCC 749 [9]
VIM-2R ACGACTGAGCGATTTGTGTG
NDM-F NDM-type GCCCAATATTATGCACCCGG 738 This study
NDM-R CTCATCACGATCATGCTGGC
OXA-48F OXA-48 variants GATTATCGGAATGCCTGCGG 845 [10]
OXA-48R CTACAAGCGCATCGAGCATCA
TEM-F TEM-type CTTGAAGACGAAAGGGCCTC 997 [11]
TEM-R TGACTCCCCGTCGTGTAGAT
SHV-F SHV-type CGCCGGGTTATTCTTATTTG 936 This study
SHV-R CGGCTTAGCGTTGCCAGT
CTXM-1F CTXM-1 variants CCGTCACGCTGTTGTTAGG 782 [8]
CTXM-1R ACGGCTTTCTGCCTTAGGTT
CTXM-9F CTXM-9 variants CAAAGAGAGTGCAACGGATG 862 [8]
CTXM-9R CCTTCGGCGATGATTCTC
CMY-1F CMY-1 variants CAACGACAATCCATCCTGTG 1,007 This study
CMY-1R GAGCCGGTCTTGTTGAAGAG
CMY-2F CMY-2 variants AGTAAGACGTTTAACGGCGTGT 749
CMY-2R TTATGCACCCATGAGGCTTT
DHA-F DHA type ACAATCGCCACCTGTTTTTC 976 This study
DHA-R TGGTGGACAGCACCATTAAA
Table 4

Sensitivity and specificity of modified-Hodge test and VITEK AST-N202 cards for the detection of CPE strains

ic-47-167-i004
Methods Antimicrobial agent (s) Sensitivity Specificity
Modified-Hodge test Ertapenem 81.4% (35/43) 100% (79/79)
Meropenem 81.4% (35/43)
Ertapenem + meropenem 88.4% (38/43)
VITEK AST-N202 card Ertapenem 100.0% (43/43) 89.9% (71/79)a
Meropenem 95.3% (41/43)
Imipenem 93.0% (40/43)

CPE, carbapenemase-producing enterobacteriaceae.

aThe results of eight carbapenem-resistant clinical CRE isolates are excluded.

Table 5

Carbapenemase-producing Enterobacteriaceae in Korea

ic-47-167-i005
Carbapenemase Species Strain MIC (µg/mL) Reference
Imipenem Meropenem
KPC-2 K. pneumoniae KPN-DK2 16 16 [13]
KPC-2 K. pneumoniae KPN1010 >256 >256 [14]
KPC-2 K. pneumoniae 6 isolates 32-128 64-256 [15]
KPC-2 K. pneumoniae 3 isolates 2-4 2-16 [16]
KPC-2 K. pneumoniae MP14 ND ≥16 [17]
GES-5 K. pneumoniae 2 isolates ND ND [18]
GES-5 K. pneumoniae 6 isolates 0.5-1 ND [19]
GES-5 E. coli BD07372 0.5 0.25 [20]
VIM-2 S. marcescens YMC00/4/1591 64 64 [21]
VIM-2 E. cloacae KU680 4 4 [22]
VIM-2 E. cloacae YMC08/12/3793 4 0.75 [23]
VIM-2 E. cloacae YMC03/4/397 4 4 [23]
NDM-1 K. pneumoniae 4 isolates 1- >128 2- >128 [24]
OXA-232 E. coli
K. pneumoniae 		2 isolates
16 isolates		 1
4-16		 0.5-1
8-16		 [25]

Acknowledgement

This study was supported by a grant (2013-E4405-01) from the Korean Center for Disease Control and Prevention, Republic of Korea.

References

1. Bergogne-Bérézin E, Towner KJ. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev. 1996; 9:148–165.
crossref
2. Gehrlein M, Leying H, Cullman W, Wendt S, Opferkuch W. Imipenem resistance in Acinetobacter baumannii is due to altered penicillin binding proteins. Chemotherapy. 1991; 37:405–412.
crossref
3. Urban C, Go E, Mariano N, Rahal JJ. Interactions of sulbactam, clavulanic acid and tazobactam with penicillin binding proteins of imipenem-resistant and susceptibile Acinetobacter baumannii. FEMS Microbiol Lett. 1995; 125:193–197.
crossref
4. Clark RB. Imipenem resistance among Acinetobacter baumannii association with reduced expression of a 33-36 kDa outer membrane protein. J Antimicrob Chemother. 1996; 38:245–251.
crossref
5. Walsh TR. Emerging carbapenemase: a global perspective. Int J Antimicrob Agents. 2010; 36:Suppl 3. S8–S14.
6. Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis. 2011; 17:1791–1798.
7. Carrër A, Frotineau N, Nordmann P. Use of ChromID extended-spectrum β-lactamase medium for detecting carbapenemase-producing Enterobacteriaceae. J Clin Microbiol. 2010; 48:1913–1914.
crossref
8. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: twenty-three informational supplement (M100-S23). Wayne, PA, USA: CLSI;2013.
9. Bae IK, Jang SJ, Kim J, Jeong SH, Cho B, Lee K. Interspecies dissemination of the bla gene encoding PER-1 extended-spectrum β-lactamase. Antimicrob Agents Chemother. 2011; 55:1305–1307.
crossref
10. Tam VH, Chang KT, Abdelraouf K, Brioso CG, Ameka M, McCaskey LA, Western JS, Caeiro JP, Garey KW. Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2010; 54:1160–1164.
crossref
11. Park KO, Son HC, Bae IK, Jeong SH. Molecular epidemiology of infection caused by OXA-23 or IMP-1 β-lactamase-producing Acinetobacter baumannii. Korean J Clin Microbiol. 2005; 8:121–129.
12. Bae IK, Lee YN, Jeong SH, Lee K, Yong D, Lee J, Hong SG, Park YJ, Choi TY, Uh Y, Shin JH, Lee WG, Ahn JY, Lee SH, Woo GJ, Kwak HS. Emergence of CTX-M-12, PER-1 and OXA-30 β-lactamase-producing Klebsiella pneumoniae. Korean J Clin Microbiol. 2006; 9:102–109.
13. Rhee JY, Park YK, Shin JY, Choi JY, Lee MY, Peck KR, Song JH, Ko KS. KPC-producing extreme drug-resistant Klebsiella pneumoniae isolate from a patient with diabetes mellitus and chronic renal failure on hemodialysis in South Korea. Antimicrob Agents Chemother. 2010; 54:2278–2279.
crossref
14. Roh KH, Lee CK, Sohn JW, Song W, Yong D, Lee K. Isolation of a Klebsiella pneumoniae isolate of sequence type 258 producing KPC-2 carbapenemase in Korea. Korean J Lab Med. 2011; 31:298–301.
crossref
15. Yoo JS, Kim HM, Yoo JI, Yang JW, Kim HS, Chung GT, Lee YS. Detection of clonal KPC-2-producing Klebsiella pneumoniae ST258 in Korea during nationwide surveillance in 2011. J Med Microbiol. 2013; 62:1338–1342.
crossref
16. Hong SK, Yong D, Kim K, Hong SS, Hong SG, Khosbayar T, Song W, Roh KH, Jeong SH, Lee K, Chong Y. First outbreak of KPC-2-producing Klebsiella pneumoniae sequence type 258 in a hospital in South Korea. J Clin Microbiol. 2013; 51:3877–3879.
crossref
17. Lee Y, Kim BS, Chun J, Yong JH, Lee YS, Yoo JS, Yong D, Hong SG, D'Souza R, Thomson KS, Lee K, Chong Y. Clonality and resistome analysis of KPC-producing Klebsiella pneumoniae strain isolated in Korea using whole genome sequencing. Biomed Res Int. 2014; 2014:352862.
18. Ryoo NH, Kim EC, Hong SG, Park YJ, Lee K, Bae IK, Song EH, Jeong SH. Dissemination of SHV-12 and CTX-M-type extended-spectrum β-lactamases among clinical isolates of Escherichia coli and Klebsiella pneumoniae and emergence of GES-3 in Korea. J Antimicrob Chemother. 2005; 56:698–702.
crossref
19. Jeong SH, Bae IK, Kim D, Hong SG, Song JS, Lee JH, Lee SH. First outbreak of Klebsiella pneumoniae clinical isolates producing GES-5 and SHV-12 extended-spectrum β-lactamases in Korea. Antimicrob Agents Chemother. 2005; 49:4809–4810.
crossref
20. Kim J, Hong SG, Bae IK, Kang JR, Jeong SH, Lee W, Lee K. Emergence of Escherichia coli sequence type ST131 carrying both the blaGES-5 and blaCTX-M-15 genes. Antimicrob Agents Chemother. 2011; 55:2974–2975.
crossref
21. Yum JH, Yong D, Lee K, Kim HS, Chong Y. A new integron carrying VIM-2 metallo-β-lactamase gene cassette in a Serratia marcescens isolate. Diagn Microbiol Infect Dis. 2002; 42:217–219.
crossref
22. Jeong SH, Lee K, Chong Y, Yum JH, Lee SH, Choi HJ, Kim JM, Park KH, Han BH, Lee SW, Jeong TS. Characterization of a new integron containing VIM-2, a metallo-β-lactamase gene cassette, in a clinical isolate of Enterobacter cloacae. J Antimicrob Chemother. 2003; 51:397–400.
crossref
23. Lee Y, Choi H, Yum JH, Kang G, Bae IK, Jeong SH, Lee K. Molecualr mechanisms of carbapenem resistance in Enterobacter cloacae clinical isolates from Korea and clinical outcome. Ann Clin Lab Sci. 2012; 42:281–286.
24. Kim MN, Yong D, An D, Chung HS, Woo JH, Lee K, Chong Y. Nosocomial clustering of NDM-1-producing Klebsiella pneumoniae sequence type 340 strains in four patients at a South Korean tertiary care hospital. J Clin Microbiol. 2012; 50:1433–1436.
crossref
25. Jeong SH, Lee KM, Lee J, Bae IK, Kim JS, Kim HS, Song W. Clonal and horizontal spread of the blaOXA-232 gene among Enterobacteriaceae in a Korean hospital. Diagn Microbiol Infect Dis. 2015; 82:70–72.
crossref
26. Yoo JS, Kim HM, Koo HS, Yand JW, Yoo JI, Kim HS, Park HK, Lee YS. Nosocomial transmission of NDM-1-producing Escherichia coli ST101 in a Korean Hospital. J Antimicrob Chemother. 2013; 68:2170–2172.
crossref
TOOLS
ORCID iDs

Il Kwon Bae
https://orcid.org/http://orcid.org/0000-0003-1633-3240

Hyun-Kyung Kang
https://orcid.org/http://orcid.org/0000-0001-5550-241X

In-Ho Jang
https://orcid.org/http://orcid.org/0000-0002-2881-5389

Woonhyoung Lee
https://orcid.org/http://orcid.org/0000-0002-2863-3788

Jung Ok Kim
https://orcid.org/http://orcid.org/0000-0002-4136-1537

Seok Hoon Jeong
https://orcid.org/http://orcid.org/0000-0001-9290-897X

Kyungwon Lee
https://orcid.org/http://orcid.org/0000-0003-3788-2134

Similar articles